Pfizer Inc. (NYSE:PFE) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Each year, approximately 500,000 cases of meningococcal disease occur worldwide due to N. meningitidis. 1 The majority of invasive meningococcal disease cases worldwide can be attributed to five N. meningitidis serogroups (A, B, C, W-135 and Y). 2 Disease caused by N. meningitidis serogroup B has been estimated at between 20,000 and 80,000 cases per year globally. 3 In 2012, approximately 40 percent of cases in the U.S. were due to meningococcal disease caused by serogroup B. 4 Despite the availability of antibiotic treatment, between 10 and 15 percent of patients with meningococcal disease die and 11 to 19 percent of those who survive are afflicted with long-term disabilities, such as brain damage, hearing loss, learning disabilities or limb amputations. 5 There is currently no meningococcal B vaccine approved for use in the United States. 2,6 “The BLA submission for bivalent rLP2086 marks an important step toward our goal of helping to protect adolescents and young adults against this difficult to diagnose and often deadly disease,” said Dr. Emilio Emini, senior vice president of Vaccine Research and Development for Pfizer Inc. “There is an urgent public health need to help prevent meningococcal B disease through vaccination, and we will continue to work closely with the FDA in our efforts to advance our vaccine candidate.” The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. Pfizer will communicate the agency’s decision. About rLP2086 Pfizer’s investigational meningococcal B vaccine targets LP2086, or factor H binding protein, which is found on the surface of the meningococcal B bacterium. 7 The gene for factor H binding protein is present in more than 1,800 meningococcal B isolates studied by Pfizer researchers. 7,8 The vaccine contains two recombinant versions of the LP2086 antigen, one representative for each of the two known genetic subfamilies of the antigen. 9 Pfizer is conducting a global clinical development program for bivalent rLP2086, which includes both Phase 2 and Phase 3 trials evaluating more than 20,000 participants, approximately 14,000 of whom will receive the investigational vaccine. 10,11,12,13,14,15,16,17 The Phase 3 program began in November 2012 with the initiation of a large scale safety study. Additional immunogenicity and safety studies are also ongoing. The FDA granted Breakthrough Therapy designation for bivalent rLP2086 in March 2014 based, in part, on data from clinical trials studying the safety and immunogenicity of bivalent rLP2086.
Clinical data from a Phase 2 study published in the Lancet Infectious Diseases in 2012 showed the investigational bivalent rLP2086 vaccine induced bactericidal antibodies in healthy adolescents aged 11 to 18 years that were broadly active against meningococcal B bacteria. 18 Safety data from the study also showed the vaccine had an acceptable safety profile in this healthy adolescent study population and supported the further evaluation of the vaccine in Phase 3 studies. 18Additionally, in two Phase 2 studies presented at the Annual Meeting of the European Society for Paediatric Diseases (ESPID) in May 2014, bivalent rLP2086 was found to elicit bactericidal responses against diverse meningococcal serogroup B test strains. 19,20 For more information on ongoing clinical trials of bivalent rLP2086, visit www.clinicaltrials.gov. Pfizer Inc.: Working together for a healthier world™ At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com. DISCLOSURE NOTICE: The information contained in this release is as of June 17, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about a product candidate, bivalent rLP2086, including its potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical trial completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results; whether and when the FDA will accept the BLA submitted for bivalent rLP2086; whether and when any biologics license applications may be filed in any other jurisdictions for bivalent rLP2086; whether and when the BLA or any such other applications may be approved by the FDA or other regulatory authorities as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in its subsequent reports on Form 10-Q and Form 8-K. 1 World Health Organization. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002; 77(40): 329-340. http://www.who.int/immunization/wer7740meningococcal_Oct02_position_paper.pdf. Accessed May 20, 2014. 2 Pinto VB, Burden R, Wagner A, Moran EE, Lee C. The Development of an Experimental Multiple Serogroups Vaccine for Neisseria meningitidis. PLoS ONE. 2013; 8(11): 1-10. 3 Kieny MP, Excier J, Girard M. Research and Development of New Vaccines Against Infectious Diseases. Am J Public Health. 2004; 94(11): 1931-1935. 4 Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network - Neisseria meningitidis, 2012. http://www.cdc.gov/abcs/reports-findings/survreports/mening12.html. Accessed May 20, 2014. 5 Centers for Disease Control and Prevention. Vaccine Information Statements (VIS) for Patients: meningococcal vaccine. http://m.cdc.gov/en/HealthSafetyTopics/HealthyLiving/Vaccines/VIS/Meningococcal. Last Updated June 18, 2013. Accessed May 20, 2014. 6 Granoff D. Review of Meningococcal Group B Vaccines. Clin Infect Dis. 2010; 50(2); 554-565. 7 Murphy E, et al. Sequence diversity of the Factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009; 200: 379-389. 8 Fletcher LD, Bernfield L, Barniak V, et al. Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein. Infect Immun. 2004; 72(4): 2088-2100. 9 McNeil LK, Zagursky RJ, Lin SL, et al. Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate to Broadly Protect Against Meningococcal Disease. Microbiol. Mol. Biol. Rev. 2013; 77(2): 234- 252. 10 ClinicalTrials.gov. A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years. http://clinicaltrials.gov/ct2/show/NCT01830855?term=B1971009&rank=1. Accessed May 20, 2014. 11 ClinicalTrials.gov. A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years. http://clinicaltrials.gov/ct2/show/NCT01352793?term=B1971014&rank=1. Accessed May 20, 2014. 12 ClinicalTrials.gov. A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age. http://clinicaltrials.gov/ct2/show/NCT01461980?term=B1971015&rank=1. Accessed May 20, 2014. 13 ClinicalTrials.gov. A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years. http://clinicaltrials.gov/ct2/show/NCT01299480?term=B1971012&rank=1. Accessed May 20, 2014. 14 ClinicalTrials.gov. A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax ® and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. http://clinicaltrials.gov/ct2/show/NCT01323270?term=B1971010&rank=1. Accessed May 20, 2014. 15 ClincalTrials.gov. A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents. http://clinicaltrials.gov/ct2/show/NCT00808028?term=B1971005&rank=1. Accessed May 20, 2014. 16 ClinicalTrials.gov. A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17. http://clinicaltrials.gov/ct2/show/NCT01461993?term=B1971011&rank=1. Accessed May 20, 2014. 17 ClinicalTrials.gov. A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. (B1971016). http://clinicaltrials.gov/ct2/show/NCT01352845?term=B1971016&rank=1. Accessed May 20, 2014. 18 Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B (MnB) bivalent rLP2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(8): 597-607. Published online ahead of print May 2012. 19 Vesikari T, Wysocki J, Kieninger D, et al. Randomized, Placebo-Controlled, Phase 2 Study of the Immunogenicity and Safety of Repevax ® Administered Concomitantly with Bivalent rLP2086 Vaccine in Healthy Adolescents. Abstract presented at: 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 6-10, 2014; Dublin, Ireland. 20 Vesikari T, Wysocki J, Kieninger D, et al. Randomized, Placebo-Controlled, Phase 2 Study of the Immunogenicity and Safety of Repevax ® Administered Concomitantly with Bivalent rLP2086 Vaccine in Healthy Adolescents. Abstract presented at: 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 6-10, 2014; Dublin, Ireland.